JPS6131099B2 - - Google Patents
Info
- Publication number
- JPS6131099B2 JPS6131099B2 JP58026887A JP2688783A JPS6131099B2 JP S6131099 B2 JPS6131099 B2 JP S6131099B2 JP 58026887 A JP58026887 A JP 58026887A JP 2688783 A JP2688783 A JP 2688783A JP S6131099 B2 JPS6131099 B2 JP S6131099B2
- Authority
- JP
- Japan
- Prior art keywords
- mol
- hydrochloride
- salt
- active ingredient
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 150000003053 piperidines Chemical class 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000003474 anti-emetic effect Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000002111 antiemetic agent Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- -1 4-(p-fluor benzoyl)-1-[3-(p -chlorobenzoyl)propyl]piperidine hydrochloride 4-(p-fluorobenzoyl)piperidine hydrochloride Chemical compound 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- DKODJPKBUYMOQW-UHFFFAOYSA-N (4-chlorophenyl)-[1-[3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]propyl]piperidin-4-yl]methanone Chemical compound C1=CC(F)=CC=C1C1(CCCN2CCC(CC2)C(=O)C=2C=CC(Cl)=CC=2)OCCO1 DKODJPKBUYMOQW-UHFFFAOYSA-N 0.000 description 2
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- IYGWDOXHCPQXKN-UHFFFAOYSA-N (4-chlorophenyl)-piperidin-4-ylmethanone Chemical compound C1=CC(Cl)=CC=C1C(=O)C1CCNCC1 IYGWDOXHCPQXKN-UHFFFAOYSA-N 0.000 description 1
- GPKDBZQZPNOBGM-UHFFFAOYSA-N (4-fluorophenyl)-piperidin-4-ylmethanone;hydron;chloride Chemical compound [Cl-].C1=CC(F)=CC=C1C(=O)C1CC[NH2+]CC1 GPKDBZQZPNOBGM-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- VTDIWMPYBAVEDY-UHFFFAOYSA-N 1-propylpiperidine Chemical compound CCCN1CCCCC1 VTDIWMPYBAVEDY-UHFFFAOYSA-N 0.000 description 1
- NYUVFOZOIZTJHA-UHFFFAOYSA-N 2-(3-chloropropyl)-1,3-dioxane Chemical compound ClCCCC1OCCCO1 NYUVFOZOIZTJHA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- OEUWUVUZNNLLBQ-UHFFFAOYSA-N 4-(3-benzoylpiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(=O)CCCN1CC(C(=O)C=2C=CC=CC=2)CCC1 OEUWUVUZNNLLBQ-UHFFFAOYSA-N 0.000 description 1
- KBFNTCWDPGVJER-UHFFFAOYSA-N 4-(4-benzoylpiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(=O)CCCN1CCC(C(=O)C=2C=CC=CC=2)CC1 KBFNTCWDPGVJER-UHFFFAOYSA-N 0.000 description 1
- ZIJIVCQJKDRJOL-UHFFFAOYSA-N 4-[4-(4-chlorobenzoyl)piperidin-1-yl]-1-(4-fluorophenyl)butan-1-one;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(=O)CCCN1CCC(C(=O)C=2C=CC(Cl)=CC=2)CC1 ZIJIVCQJKDRJOL-UHFFFAOYSA-N 0.000 description 1
- BUPKTBMYUMORNV-UHFFFAOYSA-N 4-[4-(4-fluorobenzoyl)piperidin-1-yl]-1-(4-fluorophenyl)butan-1-one;hydrochloride Chemical compound [Cl-].C1=CC(F)=CC=C1C(=O)CCC[NH+]1CCC(C(=O)C=2C=CC(F)=CC=2)CC1 BUPKTBMYUMORNV-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000251778 Squalus acanthias Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- DGEYTDCFMQMLTH-UHFFFAOYSA-N methanol;propan-2-ol Chemical compound OC.CC(C)O DGEYTDCFMQMLTH-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- TXXOWSICLRODES-UHFFFAOYSA-N phenyl(piperidin-3-yl)methanone Chemical compound C=1C=CC=CC=1C(=O)C1CCCNC1 TXXOWSICLRODES-UHFFFAOYSA-N 0.000 description 1
- DDRCHUGHUHZNKZ-UHFFFAOYSA-N phenyl(piperidin-4-yl)methanone Chemical compound C=1C=CC=CC=1C(=O)C1CCNCC1 DDRCHUGHUHZNKZ-UHFFFAOYSA-N 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Description
ãã®çºæã¯é®åå€ïŒã»ïŒâïŒãŸãã¯ïŒâïŒâãžçœ®
æãããªãžã³é¡ã®è£œæ³ã«é¢ããã ãã®çºæã®é®åå€ã¯æ¬¡ã®æ§é åŒã«ãã€ãŠç€ºãã
ãååç©ããã³ãã®è¬åŠçã«èš±å®¹ãããé žä»å å¡©
ã§ããã ïŒåŒäžR1ã¯ããã²ã³ååã§ããïŒïŒ²ã¯ããã²ã³å
åã§ããïŒïœã¯æŽæ°ïŒãïŒã§ããïŒ äžèšïŒã»ïŒâïŒãŸãã¯ïŒâïŒâãžçœ®æãããªãžã³
é¡ã®ãããã®ã¯DuncanãšHelsleyã«ä»äžãããã¢
ã¡ãªã«ç¹èš±ç¬¬3576810å·æ现æžã«é瀺ãããŠã
ãããŸããã®è£œæ³ã瀺ãããŠããã åŒã®ååç©ã¯åŒã®ãžã±ãã³ã®æ°ŽçŽ åããŠçŽ
ãããªãŠã ç°å ã«ãã€ãŠè£œé ãããã äžèšäºå³åŒäžïŒ²ãR1ããã³ïœã¯åèšå®çŸ©éã
ã§ãããåŒã®ååç©ã®è£œæ³ã¯å®æœäŸã§æŽã«è©³ã
ã瀺ãããã 掻æ§é®åå€ãšããŠçšããããååç©ã¯ãããã€
ãŠïŒã»ïŒâïŒãŸãã¯ïŒâïŒâãžçœ®æãããªãžã³é¡ã®
éåºå¡©åºããã³ãã®è¬åŠçã«èš±å®¹ãããé žä»å å¡©
ã§ãããããã¯åèšåŒãã容æã«ãããããã®
é žä»å å¡©ã¯ããã¬ã€ã³é žå¡©ããããŒã«é žå¡©ãã¢ã¹
ã³ã«ãã³é žå¡©ãå¡©é žå¡©ããã³èåæ°ŽçŽ é žå¡©ãªã©ã®
éåžžã®éæ¯æ§ã§è¬åŠçã«èš±å®¹ãããå¡©ã§ãããå¡©
é žå¡©ãç¹ã«å¥œãŸããããããå¡©ã¯åœæ¥çã§è¯ãç¥
ãããæ¹æ³ã«ããäžèšéé¢å¡©åºãé©åœãªå¡©åœ¢æç©
質ãäŸãã°ãã¬ã€ã³é žããããŒã«é žãã¢ã¹ã³ã«ã
ã³é žãå¡©é žãèåæ°ŽçŽ é žãªã©ã§åŠçããã°å®¹æã«
圢æãããã ãã®æ现æžã§ãããã²ã³ååãã¯80æªæºã®åå
éãæã€ããã²ã³ååãæå³ããã奜ãŸããã®ã¯
ã§ããã ãã®çºæã«ã¯ãç¹å®ã®ïŒã»ïŒâïŒãŸãã¯ïŒâïŒâ
ãžçœ®æãããªãžã³é¡ãšãã®å¡©é žå¡©ãæãŸãããªã
å¯äœçšã䌎ãªãããšãªãååãæå¶ã§ãããšãã
çºèŠãå«ãŸããããã®å¹æãé«ãããšãããã³å¯
äœçšã䌎ããªãããšã«ãããäžèšååç©ãè¬åŠç
æäžéå«ãçµæç©ãæäžããããšãå¯èœã§ããã°
ããã§ãªããæããã«å¥œãŸããé©çšããŠæ瀺ãã
ããé®åäœçšã®ããã«çšããããæè¬éã«ãããŠ
ã¯ããã®çºæã®çµæç©ã¯è¡å§äœäžããã³éäœå€è·¯
åå¿ãªã©ã®å¯äœçšãã»ãšãã©ãããã¯ãŸã€ããæ
ããªãã ãããããç¹å®ã®ïŒã»ïŒâïŒãŸãã¯ïŒâïŒâãžçœ®
æãããªãžã³é¡ãæäžããŠååãé»æ¢ããæ¹æ³ã
äŸçµŠããããšããã®çºæã®ç¬¬ïŒã®ç®çã§ããã第
ïŒã®ç®çã¯æãŸãããªãå¯äœçšãåæã«èªçºãã
ããšãªãé®åçµæãæãããšã®ã§ããé®åæ¹æ³ã
ãã³ããã«äœ¿çšããçµæç©ãäŸçµŠããããšã§ã
ãã第ïŒã®ç®çã¯é©åœãªããã¯ã«ãŸãã¯æ äœäžäœ
æ¿åºŠã§æäžã§ããæ°èŠæŽ»æ§æåãå«ãé®åçµæç©
ãäŸçµŠããããšã§ããã第ïŒã®ç®çã¯ãååãé»
æ¢ããããã«ç¹å®ã®ïŒã»ïŒâïŒãŸãã¯ïŒâïŒâãžçœ®
æãããªãžã³é¡ãå«ãçµæç©ãäŸçµŠããããšã§ã
ãã ãã®çºæã®ä»ã®ç®çããã³å©ç¹ã¯ä»¥äžã®èšèŒã
ãæããã«ãªãã ã¢ãã¢ã«ãã€ã³ã®å¬åå¹æã«æåæ§ã§ããããš
ã瀺ãããŠããããã°ã«ãŒã©ãã³ã«ãã»ã«å ¥ãã®
ååç©ãçµå£æäžïŒPOïŒãããå¡©é žã¢ãã¢ã«ã
ã€ã³ïŒ0.1mg/KgïŒã®ç®äžæäžïŒæéåã«è¢«æ€åå
ç©ãæäžããã 被æ€ååç©ã麻é ããªãããã°ã®å°ŸçèïŒå·ŠåŸ
足ã«ïŒã«çèå æäžïŒIMïŒãã30ååŸã«å¡©é žã¢
ãã¢ã«ãã€ã³ãæäžããïŒ0.1mg/Kgãç®äžæ
äžïŒã被æ€ååç©ã¯ãã¯ãã°ã©ã ïŒmcg.ïŒåäœã§
æäžããåååæ°ã®å¯Ÿç §çŸ€ã«æ¯ã¹ãŠã®æžå°çã調
ã¹ããåŸãããããŒã¿ããED50ïŒãã¯ãã°ã©ã
åäœïŒãå®ããããã®ããŒã¿ã¯ç¬¬è¡šã«ãŸãšã
ãã
æãããªãžã³é¡ã®è£œæ³ã«é¢ããã ãã®çºæã®é®åå€ã¯æ¬¡ã®æ§é åŒã«ãã€ãŠç€ºãã
ãååç©ããã³ãã®è¬åŠçã«èš±å®¹ãããé žä»å å¡©
ã§ããã ïŒåŒäžR1ã¯ããã²ã³ååã§ããïŒïŒ²ã¯ããã²ã³å
åã§ããïŒïœã¯æŽæ°ïŒãïŒã§ããïŒ äžèšïŒã»ïŒâïŒãŸãã¯ïŒâïŒâãžçœ®æãããªãžã³
é¡ã®ãããã®ã¯DuncanãšHelsleyã«ä»äžãããã¢
ã¡ãªã«ç¹èš±ç¬¬3576810å·æ现æžã«é瀺ãããŠã
ãããŸããã®è£œæ³ã瀺ãããŠããã åŒã®ååç©ã¯åŒã®ãžã±ãã³ã®æ°ŽçŽ åããŠçŽ
ãããªãŠã ç°å ã«ãã€ãŠè£œé ãããã äžèšäºå³åŒäžïŒ²ãR1ããã³ïœã¯åèšå®çŸ©éã
ã§ãããåŒã®ååç©ã®è£œæ³ã¯å®æœäŸã§æŽã«è©³ã
ã瀺ãããã 掻æ§é®åå€ãšããŠçšããããååç©ã¯ãããã€
ãŠïŒã»ïŒâïŒãŸãã¯ïŒâïŒâãžçœ®æãããªãžã³é¡ã®
éåºå¡©åºããã³ãã®è¬åŠçã«èš±å®¹ãããé žä»å å¡©
ã§ãããããã¯åèšåŒãã容æã«ãããããã®
é žä»å å¡©ã¯ããã¬ã€ã³é žå¡©ããããŒã«é žå¡©ãã¢ã¹
ã³ã«ãã³é žå¡©ãå¡©é žå¡©ããã³èåæ°ŽçŽ é žå¡©ãªã©ã®
éåžžã®éæ¯æ§ã§è¬åŠçã«èš±å®¹ãããå¡©ã§ãããå¡©
é žå¡©ãç¹ã«å¥œãŸããããããå¡©ã¯åœæ¥çã§è¯ãç¥
ãããæ¹æ³ã«ããäžèšéé¢å¡©åºãé©åœãªå¡©åœ¢æç©
質ãäŸãã°ãã¬ã€ã³é žããããŒã«é žãã¢ã¹ã³ã«ã
ã³é žãå¡©é žãèåæ°ŽçŽ é žãªã©ã§åŠçããã°å®¹æã«
圢æãããã ãã®æ现æžã§ãããã²ã³ååãã¯80æªæºã®åå
éãæã€ããã²ã³ååãæå³ããã奜ãŸããã®ã¯
ã§ããã ãã®çºæã«ã¯ãç¹å®ã®ïŒã»ïŒâïŒãŸãã¯ïŒâïŒâ
ãžçœ®æãããªãžã³é¡ãšãã®å¡©é žå¡©ãæãŸãããªã
å¯äœçšã䌎ãªãããšãªãååãæå¶ã§ãããšãã
çºèŠãå«ãŸããããã®å¹æãé«ãããšãããã³å¯
äœçšã䌎ããªãããšã«ãããäžèšååç©ãè¬åŠç
æäžéå«ãçµæç©ãæäžããããšãå¯èœã§ããã°
ããã§ãªããæããã«å¥œãŸããé©çšããŠæ瀺ãã
ããé®åäœçšã®ããã«çšããããæè¬éã«ãããŠ
ã¯ããã®çºæã®çµæç©ã¯è¡å§äœäžããã³éäœå€è·¯
åå¿ãªã©ã®å¯äœçšãã»ãšãã©ãããã¯ãŸã€ããæ
ããªãã ãããããç¹å®ã®ïŒã»ïŒâïŒãŸãã¯ïŒâïŒâãžçœ®
æãããªãžã³é¡ãæäžããŠååãé»æ¢ããæ¹æ³ã
äŸçµŠããããšããã®çºæã®ç¬¬ïŒã®ç®çã§ããã第
ïŒã®ç®çã¯æãŸãããªãå¯äœçšãåæã«èªçºãã
ããšãªãé®åçµæãæãããšã®ã§ããé®åæ¹æ³ã
ãã³ããã«äœ¿çšããçµæç©ãäŸçµŠããããšã§ã
ãã第ïŒã®ç®çã¯é©åœãªããã¯ã«ãŸãã¯æ äœäžäœ
æ¿åºŠã§æäžã§ããæ°èŠæŽ»æ§æåãå«ãé®åçµæç©
ãäŸçµŠããããšã§ããã第ïŒã®ç®çã¯ãååãé»
æ¢ããããã«ç¹å®ã®ïŒã»ïŒâïŒãŸãã¯ïŒâïŒâãžçœ®
æãããªãžã³é¡ãå«ãçµæç©ãäŸçµŠããããšã§ã
ãã ãã®çºæã®ä»ã®ç®çããã³å©ç¹ã¯ä»¥äžã®èšèŒã
ãæããã«ãªãã ã¢ãã¢ã«ãã€ã³ã®å¬åå¹æã«æåæ§ã§ããããš
ã瀺ãããŠããããã°ã«ãŒã©ãã³ã«ãã»ã«å ¥ãã®
ååç©ãçµå£æäžïŒPOïŒãããå¡©é žã¢ãã¢ã«ã
ã€ã³ïŒ0.1mg/KgïŒã®ç®äžæäžïŒæéåã«è¢«æ€åå
ç©ãæäžããã 被æ€ååç©ã麻é ããªãããã°ã®å°ŸçèïŒå·ŠåŸ
足ã«ïŒã«çèå æäžïŒIMïŒãã30ååŸã«å¡©é žã¢
ãã¢ã«ãã€ã³ãæäžããïŒ0.1mg/Kgãç®äžæ
äžïŒã被æ€ååç©ã¯ãã¯ãã°ã©ã ïŒmcg.ïŒåäœã§
æäžããåååæ°ã®å¯Ÿç §çŸ€ã«æ¯ã¹ãŠã®æžå°çã調
ã¹ããåŸãããããŒã¿ããED50ïŒãã¯ãã°ã©ã
åäœïŒãå®ããããã®ããŒã¿ã¯ç¬¬è¡šã«ãŸãšã
ãã
ãè¡šã
補é äŸïŒâïŒã®ååç©ã¯ãã¹ãŠæ°Žæº¶æ§ã ã€ãã
å®æœäŸïŒã®ååã¯80ïŒ ã®ããªãšãã¬ã³ã°ãªã³ãŒã«
300ãš20ïŒ ã®æ°Žãšãããªãããã¯ã«ã«æº¶è§£ããã 補é äŸ ïŒ ïŒâïŒïœâãã«ãªã«ãã³ãŸã€ã«ïŒâïŒâãïŒâïŒïœ
âãã«ãªã«ãã³ãŸã€ã«ïŒãããã«ããããªãžã³
å¡©é žå¡© 13.9ïœïŒ0.057ã¢ã«ïŒã®ïŒâïŒïœâãã«ãªã«ãã³
ãŸã€ã«ïŒãããªãžã³å¡©é žå¡©ã15.5ïœïŒ0.063ã¢
ã«ïŒã®ïŒâïŒïœâãã«ãªã«ããšãã«ïŒâïŒâïŒÏâ
ã¯ãã«ãããã³ïŒâïŒã»ïŒâãžãªããœã©ã³ããã
ã³27.6ïœïŒ0.2ã¢ã«ïŒã®çé žã«ã«ã·ãŠã ã150mlã®
ïŒâãã¿ããŒã«ã«å ¥ã20æééæµãããéãã
液ãæ¿çž®ããæ²¹ç¶æ®æž£ã50mlã®ãšãŒãã«ïŒã¡ã¿
ããŒã«æ··æ¶²ã«æº¶è§£ãã100mlã®3NHClãšå ±ã«ïŒæ
éæ¹æãããå·åŽããå±€ãåé¢ããæ°Žå±€ãå¡©åºæ§
ã«ãããšãŒãã«ã§æœåºãããåŸããšãŒãã«æœåºæ¶²
ãç¡æ°Žç¡«é žãããªãŠã ã§ä¹Ÿç¥ããéãã液ã
ãšãŒãã«æ§å¡©é žã§åŠçãããåŸãå¡©ïŒ17.2ïœïŒ74
ïŒ ïŒãã€ãœãããããŒã«ïŒã¡ã¿ããŒã«æ··æ¶²ããå
çµæ¶ããã也ç¥åŸã®èç¹ã¯255ã257âã ã€ããã
ã®å¡©é žå¡©ã®äžéšãäžåããŠè£œé ããéé¢å¡©åºã¯
133ã135âã§è解ããã åæïŒ èšç®å€ïŒC22H24ClF2NO2ïŒ ïŒïŒ£ã64.78ïŒïŒšã5.93ïŒïŒ®ã3.44 枬å®å€ïŒïŒ£ã64.77ïŒïŒšã6.02ïŒïŒ®ã3.34 補é äŸ ïŒ ïŒâïŒïœâãã«ãªã«ãã³ãŸã€ã«ïŒâïŒâãïŒâïŒïœ
âã¯ãã«ãã³ãŸã€ã«ïŒãããã«ããããªãžã³å¡©
é žå¡© ïŒâïŒïœâãã«ãªã«ãã³ãŸã€ã«ïŒãããªãžã³å¡©
é žå¡©ïŒ9.75ïœïŒ0.04ã¢ã«ïŒãïŒâïŒïœâã¯ãã«ããš
ãã«ïŒâïŒâïŒÏâã¯ãã«ãããã«ïŒâïŒã»ïŒâãž
ãªããœã©ã³ïŒ10.5ïœïŒ0.04ã¢ã«ïŒãéçé žãããª
ãŠã ïŒ13.5ïœïŒ0.16ã¢ã«ïŒããã³150mlã®ïœâã
ã¿ããŒã«ãããªãæ··åç©ã12æééæµãããç±æ
éãããã€ã«ã¿ãŒã±ãŒãããã³ãŒã³ã§æŽã€ãã
液ãããããæžå§æ¿çž®ãããæ®çç©è³ªãæå°é
ã®ç¡æ°Žãšã¿ããŒã«ã«æº¶è§£ãã6NHClãå ãã0.5
æéæ¹æãããæ°Žãå ããçããåºäœå¡©é žå¡©ã
éã«ããåé¢ãããã€ãœãããããŒã«ïŒã¡ã¿ããŒ
ã«ããåçµæ¶ããŠ6.3ïœïŒ41ïŒ ïŒã®å¡©é žå¡©
ïŒmp250ã252âïŒãåŸãã åæïŒ èšç®å€ïŒC22H24Cl2FNO2ïŒ ïŒïŒ£ã62.27ïŒïŒšã5.46ïŒïŒ®ã3.30 枬å®å€ïŒïŒ£ã62.54ïŒïŒšã5.72ïŒïŒ®ã3.29 補é äŸ ïŒ ïŒâïŒïœâã¯ãã«ãã³ãŸã€ã«ïŒâïŒâãïŒâïŒïœâ
ãã«ãªã«ãã³ãŸã€ã«ïŒãããã«ããããªãžã³å¡©
é žå¡© 10ïœïŒ0.023ã¢ã«ïŒã®ïŒâïŒïœâãã«ãªã«ããšã
ã«ïŒâïŒâïœïŒâãïŒâïŒïœâã¯ãã«ãã³ãŸã€ã«ïŒã
ããªãžãã«ããããã«ïœâïŒã»ïŒâãžãªããœã©ã³
ã100mlã®6NHClãš100mlã®ã¡ã¿ããŒã«ã®æ··æ¶²äžã§
å æž©ããªããïŒæéæ¹æããŠæº¶æ¶²ãšãããããæŸ
å·ãããçæç©ã¯å¡©é žå¡©ãšããŠåé¢ãããïŒïœã®
å¡©ãéã«ããéããïŒmp261â266âïŒãåç61
ïŒ ãã¡ã¿ããŒã«ïŒã€ãœãããããŒã«ããåçµæ¶ã
ãŠ4.0ïœã®å¡©ãåŸããäžèšéã«ããåŸã液ã
ç¡æ°ŽãšãŒãã«ã§åŠçããŠæŽã«0.5ïœã®å¡©ãæåºã
ãããïŒã€ã®ãã©ã¯ã·ãšã³ã¯åäžã®èç¹ïŒ264ã
266âïŒãæã€ãŠããã åæïŒ èšç®å€ïŒC22H24Cl2FNO2ïŒ ïŒïŒ£ã62.27ïŒïŒšã5.70ïŒïŒ®ã3.30 枬å®å€ïŒïŒ£ã62.49ïŒïŒšã5.71ïŒïŒ®ã3.32 ïŒâïŒïœâãã«ãªã«ããšãã«ïŒâïŒâïœïŒâãïŒâ
ïŒïœâã¯ãã«ãã³ãŸã€ã«ïŒãããªãžãã«ãããã
ã«ïœâïŒã»ïŒâãžãªããœã©ã³ãã8.4ïœïŒ0.10ã¢
ã«ïŒã®éçé žãããªãŠã ãå«ã125mlã®éæµïœâ
ãã¿ããŒã«äžã§10ïœïŒ0.045ã¢ã«ïŒã®ïŒâïŒïœâã¯
ãã«ãã³ãŸã€ã«ïŒãããªãžã³ãš13.6ïœïŒ0.0555ã¢
ã«ïŒã®ïŒâïŒïœâãã«ãªã«ããšãã«ïŒâïŒâïŒÏâ
ã¯ãã«ãããã«ïŒâïŒã»ïŒâãžãªããµã³ã22æé
åå¿ãããããšã«ãã補é ãããå·åŽããé
ããæžå§æ¿çž®ããŠ21.3ïœïŒ100ïŒ åçïŒã®æ²¹ç¶ç©
ãåŸãããã®æ²¹ç¶ç©ã¯ç åã«ããçµæ¶åããã 補é äŸ ïŒ ïŒâïŒïœâã¯ãã«ãã³ãŸã€ã«ïŒâïŒâãïŒâïŒïœâ
ã¯ãã«ãã³ãŸã€ã«ïŒãããã«ããããªãžã³å¡©é ž
å¡© ïŒâïŒïœâã¯ãã«ãã³ãŸã€ã«ïŒãããªãžã³å¡©é ž
å¡©ïŒ10.5ïœïŒ0.04ã¢ã«ïŒãïŒâïŒïœâã¯ãã«ããšã
ã«ïŒâïŒâïŒÏâã¯ãã«ãããã«ïŒâïŒã»ïŒâãžãª
ããœã©ã³ïŒ10.5ïœïŒ0.04ã¢ã«ïŒãããã³éçé žã
ããªãŠã ïŒ13.5ïœïŒ0.16ã¢ã«ïŒãïœâãã¿ããŒã«
äžã§12æééæµãããç±æéãã液ãæžå§æ¿
çž®ããæ®çç©è³ªããšã¿ããŒã«ïŒ6NHCl混液äžã«æº¶
解ããã0.5æéæ¹æããåé¢ããå¡©é žå¡©ãå
ãããã€ãœãããããŒã«âã¡ã¿ããŒã«ïŒçïŒãã
åçµæ¶ããŠ9.2ïœïŒ57ïŒ ïŒã®å¡©é žå¡©ïŒmp253ã256
ãïŒãåŸãã åæïŒ èšç®å€ïŒC22H24Cl3NO2ïŒ ïŒïŒ£ã59.94ïŒïŒšã5.26ïŒïŒ®ã3.18 枬å®å€ïŒïŒ£ã60.07ïŒïŒšã5.42ïŒïŒ®ã3.23 補é äŸ ïŒ ïŒâãã³ãŸã€ã«âïŒâãïŒâïŒïœâãã«ãªã«ãã³
ãŸã€ã«ïŒâãããã«ããããªãžã³å¡©é žå¡© 7.0ïœïŒ0.037ã¢ã«ïŒã®ïŒâãã³ãŸã€ã«ãããªãž
ã³ã9.8ïœïŒ0.040ã¢ã«ïŒã®ïŒâããšãã«âïŒâ
ïŒÏâã¯ãã«ãããã«ïŒâïŒã»ïŒâãžãªããœã©ã³ã
20ïœã®K2CO3ããã³100mlã®ïŒâãã¿ããŒã«ãã
ãªãæ¹ææ··åç©ã16æééæµããå·åŽããé
ããæžå§ã§æº¶åªãèžçºçå»ãããæ®çæ²¹ç¶ç©ã
100mlã®3NHClããã³100mlã®ãšã¿ããŒã«ãšå ±ã«ïŒ
æéæ¹æããã50ïŒ NaOHã§å¡©åºæ§ã«ããåé¢ã
ãæ²¹ç¶ç©ããã³ãŒã³ã§æœåºãããæœåºæ¶²ãããã
ãŠãæ°Žã§æŽããç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ãã溶åª
ãèžçºçå»ãããæ®æž£ãã€ãœãããããŒã«ã«æº¶è§£
ãããšãŒãã«æ§HClã§åŠçããã圢æããçœè²çµ
æ¶çæç©ãã€ãœãããããŒã«ïŒãšã¿ããŒã«æ··æ¶²ã
ãåçµæ¶ãããå¡©ã¯8.4ïœïŒ59ïŒ åçïŒããã230
ã233âã§æº¶èããã åæïŒ èšç®å€ïŒC22H25ClFNO2ïŒ ïŒïŒ£ã67.77ïŒïŒšã6.46ïŒïŒ®ã3.59 枬å®å€ïŒïŒ£ã67.58ïŒïŒšã6.41ïŒïŒ®ã3.61 補é äŸ ïŒ ïŒâãã³ãŸã€ã«âïŒâãïŒâïŒïœâãã«ãªã«ãã³
ãŸã€ã«ïŒãããã«ããããªãžã³å¡©é žå¡© 5.7ïœïŒ0.030ã¢ã«ïŒã®ïŒâãã³ãŸã€ã«ãããªãž
ã³ã8.3ïœïŒ0.034ã¢ã«ïŒã®ïŒâïŒïœâãã«ãªã«ã
ã³ãŸã€ã«ïŒâïŒâïŒÏâã¯ãã«ãããã«ïŒâïŒã»ïŒ
âãžãªããœã©ã³ã14ïœã®çé žã«ãªãŠã ããã³100
mlã®ïŒâãã¿ããŒã«ãããªãæ··åç©ã16æééæµ
ããå·åŽããéãã溶åªãæžå§èžçºãããæ®ç
æ²¹ç¶ç©ã100mlã®3NHClããã³100mlã®ãšã¿ããŒã«
ãšå ±ã«ïŒæéæ¹æãã50ïŒ NaOHã§å¡©åºæ§ã«ãã
åé¢ããæ²¹ç¶ç©ããã³ãŒã³ã§æœåºãããæœåºæ¶²ã
ããããæ°Žã§æŽããç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ãã
溶åªãæžå§èžçºãããæ®çç¶ç©ãã€ãœãããããŒ
ã«ã«æº¶è§£ãããšãŒãã«æ§HClã§åŠçããã圢æã
ããçœè²çµæ¶å¡©ã¯ã€ãœãããããŒã«ããå床çµæ¶
åŸ206ã208âã§å解ã䌎ã溶èãã5.1ïœïŒ44ïŒ
åçïŒãã€ãã åæïŒ èšç®å€ïŒC22H25NO2ClFïŒ ïŒïŒ£ã67.77ïŒïŒšã6.46ïŒïŒ®ã3.59 枬å®å€ïŒïŒ£ã67.96ïŒïŒšã6.40ïŒïŒ®ã3.65 å®æœäŸ ïŒ ïŒâïŒïœâãã«ãªã«âαâããããã·ãã³ãž
ã«ïŒâïŒâãïŒâïŒïœâãã«ãªã«âαâãããã
ã·ïŒãããã«ããããªãžã³ 4.3ïœïŒ0.0116ã¢ã«ïŒã®ïŒâïŒïœâãã«ãªã«ãã³
ãŸã€ã«ïŒâïŒâãïŒâïŒïœâãã«ãªã«ãã³ãŸã€ã«ïŒ
ãããã«ããããªãžã³ã100mlã®ç¡æ°Žãšã¿ããŒã«
ã«å«ããŠåŸã50âã®æ¹ææžæ¿æ¶²ã«å°éãã€1.9ïœ
ïŒ0.05ã¢ã«ïŒã®æ°ŽçŽ åããŠçŽ ãããªãŠã ãå ã
ãããã¹ãŠã®åçŽ åããŠçŽ ãããªãŠã ãå ããåŸ
ã«æ¹æã50âã§ïŒæéç¶ããã20mlã®3NHClãã
ã€ãããšæ»Žäžãããåå¿æ··åç©ãçŽ400mlã®æ°Žã«
溶é¢ããNaOHãããã«å¡©åºæ§ã«ãããã¯ããã
ã«ã ã§æœåºããæœåºæ¶²ãç¡æ°Žç¡«é žãã°ãã·ãŠã ã§
也ç¥ãããéãã液ãæžå§æ¿çž®ããŠ4.8ïœã®
æ²¹ç¶ç©ãåŸããããã¯ã€ãœãªã¯ã¿ã³ã§ç åããã
çµæ¶åãããåŸãç²çæç©ã¯4.1ïœïŒ94ã95ïŒ ïŒ
ããã115ã117âã§è解ãããã€ãœãªã¯ã¿ã³ïŒã
ã³ãŒã³ããåçµæ¶ããŠmp115ã117âã®çæç©ã
3.6ïœåŸãã åæïŒ èšç®å€ïŒC22H27F2NO2ïŒ ïŒïŒ£ã70.38ïŒïŒšã7.25ïŒïŒ®ã3.73 枬å®å€ïŒïŒ£ã70.42ïŒïŒšã7.35ïŒïŒ®ã3.74 以äžã®è¬çåŠçã«æŽ»æ§ãªååç©ã®æå¹éãæ§ã
ãªæ¹æ³ãäŸãã°ã«ãã»ã«ãŸãã¯é å€ãšããŠçµå£ç
ã«ãæ» è溶液ãŸãã¯æžæ¿æ¶²ã®åœ¢ã§éçµå£çã«ãã
ããŠå Žåã«ãã€ãŠã¯æ» è溶液ã®åœ¢ã§éèå ã«ãã§
人éãå«ãåç©ã«æäžã§ããããããè¬ç©ã¯åè¬
ã®åœ¢ã§ãŸãã¯åžå ¥æ³ã«ãã€ãŠçŽè žã«æäžããããš
ãã§ããããã®çºæã®éé¢å¡©åºã¢ãã³ååç©ã¯ã
ã®ãŸãã§æå¹ã§ã¯ãããã䟿å©ã«çµæ¶åã§ããã
ãšã溶解æ§ãé«ãããšãªã©ã«ããéæ¯æ§é žä»å å¡©
ã®åœ¢ã§åŠæ¹ããæäžããããšã奜ãŸãããããã
掻æ§ååç©ãç£å»åŠçã«äœ¿çšããæã«ã¯ã飌æãŸ
ãã¯é£²ææ°Žã®æ·»å ç©ãšããŠãã®ãŸãŸäžããããšã
ã§ããã ãã®çºæã®æŽ»æ§ç©è³ªã¯éåžžã«å°éïŒ0.1mgã»ã©
å°ãªããŠãïŒã§ãçç¶ã軜ãæããŸãã¯äººéãå«
ãæ¯èŒçäœéã®å°ãªãåç©ã«æäžããæã«ã¯æå¹
ã§ã¯ããããåäœæäžéã¯éåžž0.5ãïŒãŸãã¯ïŒ
mgã§ããããã¡ããå±æ¥ã®å Žåã«ã¯ïŒãïŒmgã§ã
ãããåäœéãšããŠã¯ïŒãïŒmgãæé©éãšæãã
ããããã掻æ§å€ã¯ä»ã®è¬çåŠç掻æ§å€ãŸãã¯ç·©
è¡¡ç©ãå¶é žè¬ãªã©ãšçµã¿åãããŠæäžã§ããã掻
æ§æåãæå¹éåŸãããããšã®ã¿ãå¿ èŠã§ããã
æããã«æ°åäœæäžéãã»ãŒåæã«æäžã§ããã ãã®çºæã®æ°èŠçµæç©äžã«äœ¿çšã§ããè¬åŠçæ
äœã¯åºäœãããã¯æ¶²äœã§ãããåºäœæ äœãšããŠã¯
ä¹³ç³ã殿ç²ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãã³ãŒã³
ã¹ã¿ãŒãããªã³é žäºã«ã«ã·ãŠã ããŒã©ãã³ããã³
ã¹ãã¢ãªã³é žã«ã«ã·ãŠã ãæããããããããã«
éããªãã液äœæ äœãšããŠã¯ããŒãããæ²¹ããªãª
ãŒãæ²¹ããŽãæ²¹ããã³æ°Žãæããããããããã«
éããªãã 次ã®åŠæ¹äŸã¯ãã®çºæã®è¬çåŠçã«æŽ»æ§ãªåå
ç©ã«å¯Ÿãã代衚äŸã§ããã åŠæ¹äŸ (1) ã«ãã»ã« ïŒã«ãã»ã«ã«0.5ã1.0ã2.0ããã³5.0mgã®æŽ»
æ§æåãå«ãã«ãã»ã«ã補é ããã æ å mgïŒã«ãã»ã« 掻æ§æåãå¡©ãšã㊠0.5 ä¹³ ç³ 325.0 殿 ç² 104.5 ã¹ãã¢ãªã³é žãã°ãã·ãŠã 5.0 åèš435.0 æŽã«å€éã®æŽ»æ§æåãå«ãä»ã«ãã»ã«åŠæ¹ç©
ã¯æ¬¡ã®éãã§ããã
å®æœäŸïŒã®ååã¯80ïŒ ã®ããªãšãã¬ã³ã°ãªã³ãŒã«
300ãš20ïŒ ã®æ°Žãšãããªãããã¯ã«ã«æº¶è§£ããã 補é äŸ ïŒ ïŒâïŒïœâãã«ãªã«ãã³ãŸã€ã«ïŒâïŒâãïŒâïŒïœ
âãã«ãªã«ãã³ãŸã€ã«ïŒãããã«ããããªãžã³
å¡©é žå¡© 13.9ïœïŒ0.057ã¢ã«ïŒã®ïŒâïŒïœâãã«ãªã«ãã³
ãŸã€ã«ïŒãããªãžã³å¡©é žå¡©ã15.5ïœïŒ0.063ã¢
ã«ïŒã®ïŒâïŒïœâãã«ãªã«ããšãã«ïŒâïŒâïŒÏâ
ã¯ãã«ãããã³ïŒâïŒã»ïŒâãžãªããœã©ã³ããã
ã³27.6ïœïŒ0.2ã¢ã«ïŒã®çé žã«ã«ã·ãŠã ã150mlã®
ïŒâãã¿ããŒã«ã«å ¥ã20æééæµãããéãã
液ãæ¿çž®ããæ²¹ç¶æ®æž£ã50mlã®ãšãŒãã«ïŒã¡ã¿
ããŒã«æ··æ¶²ã«æº¶è§£ãã100mlã®3NHClãšå ±ã«ïŒæ
éæ¹æãããå·åŽããå±€ãåé¢ããæ°Žå±€ãå¡©åºæ§
ã«ãããšãŒãã«ã§æœåºãããåŸããšãŒãã«æœåºæ¶²
ãç¡æ°Žç¡«é žãããªãŠã ã§ä¹Ÿç¥ããéãã液ã
ãšãŒãã«æ§å¡©é žã§åŠçãããåŸãå¡©ïŒ17.2ïœïŒ74
ïŒ ïŒãã€ãœãããããŒã«ïŒã¡ã¿ããŒã«æ··æ¶²ããå
çµæ¶ããã也ç¥åŸã®èç¹ã¯255ã257âã ã€ããã
ã®å¡©é žå¡©ã®äžéšãäžåããŠè£œé ããéé¢å¡©åºã¯
133ã135âã§è解ããã åæïŒ èšç®å€ïŒC22H24ClF2NO2ïŒ ïŒïŒ£ã64.78ïŒïŒšã5.93ïŒïŒ®ã3.44 枬å®å€ïŒïŒ£ã64.77ïŒïŒšã6.02ïŒïŒ®ã3.34 補é äŸ ïŒ ïŒâïŒïœâãã«ãªã«ãã³ãŸã€ã«ïŒâïŒâãïŒâïŒïœ
âã¯ãã«ãã³ãŸã€ã«ïŒãããã«ããããªãžã³å¡©
é žå¡© ïŒâïŒïœâãã«ãªã«ãã³ãŸã€ã«ïŒãããªãžã³å¡©
é žå¡©ïŒ9.75ïœïŒ0.04ã¢ã«ïŒãïŒâïŒïœâã¯ãã«ããš
ãã«ïŒâïŒâïŒÏâã¯ãã«ãããã«ïŒâïŒã»ïŒâãž
ãªããœã©ã³ïŒ10.5ïœïŒ0.04ã¢ã«ïŒãéçé žãããª
ãŠã ïŒ13.5ïœïŒ0.16ã¢ã«ïŒããã³150mlã®ïœâã
ã¿ããŒã«ãããªãæ··åç©ã12æééæµãããç±æ
éãããã€ã«ã¿ãŒã±ãŒãããã³ãŒã³ã§æŽã€ãã
液ãããããæžå§æ¿çž®ãããæ®çç©è³ªãæå°é
ã®ç¡æ°Žãšã¿ããŒã«ã«æº¶è§£ãã6NHClãå ãã0.5
æéæ¹æãããæ°Žãå ããçããåºäœå¡©é žå¡©ã
éã«ããåé¢ãããã€ãœãããããŒã«ïŒã¡ã¿ããŒ
ã«ããåçµæ¶ããŠ6.3ïœïŒ41ïŒ ïŒã®å¡©é žå¡©
ïŒmp250ã252âïŒãåŸãã åæïŒ èšç®å€ïŒC22H24Cl2FNO2ïŒ ïŒïŒ£ã62.27ïŒïŒšã5.46ïŒïŒ®ã3.30 枬å®å€ïŒïŒ£ã62.54ïŒïŒšã5.72ïŒïŒ®ã3.29 補é äŸ ïŒ ïŒâïŒïœâã¯ãã«ãã³ãŸã€ã«ïŒâïŒâãïŒâïŒïœâ
ãã«ãªã«ãã³ãŸã€ã«ïŒãããã«ããããªãžã³å¡©
é žå¡© 10ïœïŒ0.023ã¢ã«ïŒã®ïŒâïŒïœâãã«ãªã«ããšã
ã«ïŒâïŒâïœïŒâãïŒâïŒïœâã¯ãã«ãã³ãŸã€ã«ïŒã
ããªãžãã«ããããã«ïœâïŒã»ïŒâãžãªããœã©ã³
ã100mlã®6NHClãš100mlã®ã¡ã¿ããŒã«ã®æ··æ¶²äžã§
å æž©ããªããïŒæéæ¹æããŠæº¶æ¶²ãšãããããæŸ
å·ãããçæç©ã¯å¡©é žå¡©ãšããŠåé¢ãããïŒïœã®
å¡©ãéã«ããéããïŒmp261â266âïŒãåç61
ïŒ ãã¡ã¿ããŒã«ïŒã€ãœãããããŒã«ããåçµæ¶ã
ãŠ4.0ïœã®å¡©ãåŸããäžèšéã«ããåŸã液ã
ç¡æ°ŽãšãŒãã«ã§åŠçããŠæŽã«0.5ïœã®å¡©ãæåºã
ãããïŒã€ã®ãã©ã¯ã·ãšã³ã¯åäžã®èç¹ïŒ264ã
266âïŒãæã€ãŠããã åæïŒ èšç®å€ïŒC22H24Cl2FNO2ïŒ ïŒïŒ£ã62.27ïŒïŒšã5.70ïŒïŒ®ã3.30 枬å®å€ïŒïŒ£ã62.49ïŒïŒšã5.71ïŒïŒ®ã3.32 ïŒâïŒïœâãã«ãªã«ããšãã«ïŒâïŒâïœïŒâãïŒâ
ïŒïœâã¯ãã«ãã³ãŸã€ã«ïŒãããªãžãã«ãããã
ã«ïœâïŒã»ïŒâãžãªããœã©ã³ãã8.4ïœïŒ0.10ã¢
ã«ïŒã®éçé žãããªãŠã ãå«ã125mlã®éæµïœâ
ãã¿ããŒã«äžã§10ïœïŒ0.045ã¢ã«ïŒã®ïŒâïŒïœâã¯
ãã«ãã³ãŸã€ã«ïŒãããªãžã³ãš13.6ïœïŒ0.0555ã¢
ã«ïŒã®ïŒâïŒïœâãã«ãªã«ããšãã«ïŒâïŒâïŒÏâ
ã¯ãã«ãããã«ïŒâïŒã»ïŒâãžãªããµã³ã22æé
åå¿ãããããšã«ãã補é ãããå·åŽããé
ããæžå§æ¿çž®ããŠ21.3ïœïŒ100ïŒ åçïŒã®æ²¹ç¶ç©
ãåŸãããã®æ²¹ç¶ç©ã¯ç åã«ããçµæ¶åããã 補é äŸ ïŒ ïŒâïŒïœâã¯ãã«ãã³ãŸã€ã«ïŒâïŒâãïŒâïŒïœâ
ã¯ãã«ãã³ãŸã€ã«ïŒãããã«ããããªãžã³å¡©é ž
å¡© ïŒâïŒïœâã¯ãã«ãã³ãŸã€ã«ïŒãããªãžã³å¡©é ž
å¡©ïŒ10.5ïœïŒ0.04ã¢ã«ïŒãïŒâïŒïœâã¯ãã«ããšã
ã«ïŒâïŒâïŒÏâã¯ãã«ãããã«ïŒâïŒã»ïŒâãžãª
ããœã©ã³ïŒ10.5ïœïŒ0.04ã¢ã«ïŒãããã³éçé žã
ããªãŠã ïŒ13.5ïœïŒ0.16ã¢ã«ïŒãïœâãã¿ããŒã«
äžã§12æééæµãããç±æéãã液ãæžå§æ¿
çž®ããæ®çç©è³ªããšã¿ããŒã«ïŒ6NHCl混液äžã«æº¶
解ããã0.5æéæ¹æããåé¢ããå¡©é žå¡©ãå
ãããã€ãœãããããŒã«âã¡ã¿ããŒã«ïŒçïŒãã
åçµæ¶ããŠ9.2ïœïŒ57ïŒ ïŒã®å¡©é žå¡©ïŒmp253ã256
ãïŒãåŸãã åæïŒ èšç®å€ïŒC22H24Cl3NO2ïŒ ïŒïŒ£ã59.94ïŒïŒšã5.26ïŒïŒ®ã3.18 枬å®å€ïŒïŒ£ã60.07ïŒïŒšã5.42ïŒïŒ®ã3.23 補é äŸ ïŒ ïŒâãã³ãŸã€ã«âïŒâãïŒâïŒïœâãã«ãªã«ãã³
ãŸã€ã«ïŒâãããã«ããããªãžã³å¡©é žå¡© 7.0ïœïŒ0.037ã¢ã«ïŒã®ïŒâãã³ãŸã€ã«ãããªãž
ã³ã9.8ïœïŒ0.040ã¢ã«ïŒã®ïŒâããšãã«âïŒâ
ïŒÏâã¯ãã«ãããã«ïŒâïŒã»ïŒâãžãªããœã©ã³ã
20ïœã®K2CO3ããã³100mlã®ïŒâãã¿ããŒã«ãã
ãªãæ¹ææ··åç©ã16æééæµããå·åŽããé
ããæžå§ã§æº¶åªãèžçºçå»ãããæ®çæ²¹ç¶ç©ã
100mlã®3NHClããã³100mlã®ãšã¿ããŒã«ãšå ±ã«ïŒ
æéæ¹æããã50ïŒ NaOHã§å¡©åºæ§ã«ããåé¢ã
ãæ²¹ç¶ç©ããã³ãŒã³ã§æœåºãããæœåºæ¶²ãããã
ãŠãæ°Žã§æŽããç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ãã溶åª
ãèžçºçå»ãããæ®æž£ãã€ãœãããããŒã«ã«æº¶è§£
ãããšãŒãã«æ§HClã§åŠçããã圢æããçœè²çµ
æ¶çæç©ãã€ãœãããããŒã«ïŒãšã¿ããŒã«æ··æ¶²ã
ãåçµæ¶ãããå¡©ã¯8.4ïœïŒ59ïŒ åçïŒããã230
ã233âã§æº¶èããã åæïŒ èšç®å€ïŒC22H25ClFNO2ïŒ ïŒïŒ£ã67.77ïŒïŒšã6.46ïŒïŒ®ã3.59 枬å®å€ïŒïŒ£ã67.58ïŒïŒšã6.41ïŒïŒ®ã3.61 補é äŸ ïŒ ïŒâãã³ãŸã€ã«âïŒâãïŒâïŒïœâãã«ãªã«ãã³
ãŸã€ã«ïŒãããã«ããããªãžã³å¡©é žå¡© 5.7ïœïŒ0.030ã¢ã«ïŒã®ïŒâãã³ãŸã€ã«ãããªãž
ã³ã8.3ïœïŒ0.034ã¢ã«ïŒã®ïŒâïŒïœâãã«ãªã«ã
ã³ãŸã€ã«ïŒâïŒâïŒÏâã¯ãã«ãããã«ïŒâïŒã»ïŒ
âãžãªããœã©ã³ã14ïœã®çé žã«ãªãŠã ããã³100
mlã®ïŒâãã¿ããŒã«ãããªãæ··åç©ã16æééæµ
ããå·åŽããéãã溶åªãæžå§èžçºãããæ®ç
æ²¹ç¶ç©ã100mlã®3NHClããã³100mlã®ãšã¿ããŒã«
ãšå ±ã«ïŒæéæ¹æãã50ïŒ NaOHã§å¡©åºæ§ã«ãã
åé¢ããæ²¹ç¶ç©ããã³ãŒã³ã§æœåºãããæœåºæ¶²ã
ããããæ°Žã§æŽããç¡«é žãã°ãã·ãŠã ã§ä¹Ÿç¥ãã
溶åªãæžå§èžçºãããæ®çç¶ç©ãã€ãœãããããŒ
ã«ã«æº¶è§£ãããšãŒãã«æ§HClã§åŠçããã圢æã
ããçœè²çµæ¶å¡©ã¯ã€ãœãããããŒã«ããå床çµæ¶
åŸ206ã208âã§å解ã䌎ã溶èãã5.1ïœïŒ44ïŒ
åçïŒãã€ãã åæïŒ èšç®å€ïŒC22H25NO2ClFïŒ ïŒïŒ£ã67.77ïŒïŒšã6.46ïŒïŒ®ã3.59 枬å®å€ïŒïŒ£ã67.96ïŒïŒšã6.40ïŒïŒ®ã3.65 å®æœäŸ ïŒ ïŒâïŒïœâãã«ãªã«âαâããããã·ãã³ãž
ã«ïŒâïŒâãïŒâïŒïœâãã«ãªã«âαâãããã
ã·ïŒãããã«ããããªãžã³ 4.3ïœïŒ0.0116ã¢ã«ïŒã®ïŒâïŒïœâãã«ãªã«ãã³
ãŸã€ã«ïŒâïŒâãïŒâïŒïœâãã«ãªã«ãã³ãŸã€ã«ïŒ
ãããã«ããããªãžã³ã100mlã®ç¡æ°Žãšã¿ããŒã«
ã«å«ããŠåŸã50âã®æ¹ææžæ¿æ¶²ã«å°éãã€1.9ïœ
ïŒ0.05ã¢ã«ïŒã®æ°ŽçŽ åããŠçŽ ãããªãŠã ãå ã
ãããã¹ãŠã®åçŽ åããŠçŽ ãããªãŠã ãå ããåŸ
ã«æ¹æã50âã§ïŒæéç¶ããã20mlã®3NHClãã
ã€ãããšæ»Žäžãããåå¿æ··åç©ãçŽ400mlã®æ°Žã«
溶é¢ããNaOHãããã«å¡©åºæ§ã«ãããã¯ããã
ã«ã ã§æœåºããæœåºæ¶²ãç¡æ°Žç¡«é žãã°ãã·ãŠã ã§
也ç¥ãããéãã液ãæžå§æ¿çž®ããŠ4.8ïœã®
æ²¹ç¶ç©ãåŸããããã¯ã€ãœãªã¯ã¿ã³ã§ç åããã
çµæ¶åãããåŸãç²çæç©ã¯4.1ïœïŒ94ã95ïŒ ïŒ
ããã115ã117âã§è解ãããã€ãœãªã¯ã¿ã³ïŒã
ã³ãŒã³ããåçµæ¶ããŠmp115ã117âã®çæç©ã
3.6ïœåŸãã åæïŒ èšç®å€ïŒC22H27F2NO2ïŒ ïŒïŒ£ã70.38ïŒïŒšã7.25ïŒïŒ®ã3.73 枬å®å€ïŒïŒ£ã70.42ïŒïŒšã7.35ïŒïŒ®ã3.74 以äžã®è¬çåŠçã«æŽ»æ§ãªååç©ã®æå¹éãæ§ã
ãªæ¹æ³ãäŸãã°ã«ãã»ã«ãŸãã¯é å€ãšããŠçµå£ç
ã«ãæ» è溶液ãŸãã¯æžæ¿æ¶²ã®åœ¢ã§éçµå£çã«ãã
ããŠå Žåã«ãã€ãŠã¯æ» è溶液ã®åœ¢ã§éèå ã«ãã§
人éãå«ãåç©ã«æäžã§ããããããè¬ç©ã¯åè¬
ã®åœ¢ã§ãŸãã¯åžå ¥æ³ã«ãã€ãŠçŽè žã«æäžããããš
ãã§ããããã®çºæã®éé¢å¡©åºã¢ãã³ååç©ã¯ã
ã®ãŸãã§æå¹ã§ã¯ãããã䟿å©ã«çµæ¶åã§ããã
ãšã溶解æ§ãé«ãããšãªã©ã«ããéæ¯æ§é žä»å å¡©
ã®åœ¢ã§åŠæ¹ããæäžããããšã奜ãŸãããããã
掻æ§ååç©ãç£å»åŠçã«äœ¿çšããæã«ã¯ã飌æãŸ
ãã¯é£²ææ°Žã®æ·»å ç©ãšããŠãã®ãŸãŸäžããããšã
ã§ããã ãã®çºæã®æŽ»æ§ç©è³ªã¯éåžžã«å°éïŒ0.1mgã»ã©
å°ãªããŠãïŒã§ãçç¶ã軜ãæããŸãã¯äººéãå«
ãæ¯èŒçäœéã®å°ãªãåç©ã«æäžããæã«ã¯æå¹
ã§ã¯ããããåäœæäžéã¯éåžž0.5ãïŒãŸãã¯ïŒ
mgã§ããããã¡ããå±æ¥ã®å Žåã«ã¯ïŒãïŒmgã§ã
ãããåäœéãšããŠã¯ïŒãïŒmgãæé©éãšæãã
ããããã掻æ§å€ã¯ä»ã®è¬çåŠç掻æ§å€ãŸãã¯ç·©
è¡¡ç©ãå¶é žè¬ãªã©ãšçµã¿åãããŠæäžã§ããã掻
æ§æåãæå¹éåŸãããããšã®ã¿ãå¿ èŠã§ããã
æããã«æ°åäœæäžéãã»ãŒåæã«æäžã§ããã ãã®çºæã®æ°èŠçµæç©äžã«äœ¿çšã§ããè¬åŠçæ
äœã¯åºäœãããã¯æ¶²äœã§ãããåºäœæ äœãšããŠã¯
ä¹³ç³ã殿ç²ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ãã³ãŒã³
ã¹ã¿ãŒãããªã³é žäºã«ã«ã·ãŠã ããŒã©ãã³ããã³
ã¹ãã¢ãªã³é žã«ã«ã·ãŠã ãæããããããããã«
éããªãã液äœæ äœãšããŠã¯ããŒãããæ²¹ããªãª
ãŒãæ²¹ããŽãæ²¹ããã³æ°Žãæããããããããã«
éããªãã 次ã®åŠæ¹äŸã¯ãã®çºæã®è¬çåŠçã«æŽ»æ§ãªåå
ç©ã«å¯Ÿãã代衚äŸã§ããã åŠæ¹äŸ (1) ã«ãã»ã« ïŒã«ãã»ã«ã«0.5ã1.0ã2.0ããã³5.0mgã®æŽ»
æ§æåãå«ãã«ãã»ã«ã補é ããã æ å mgïŒã«ãã»ã« 掻æ§æåãå¡©ãšã㊠0.5 ä¹³ ç³ 325.0 殿 ç² 104.5 ã¹ãã¢ãªã³é žãã°ãã·ãŠã 5.0 åèš435.0 æŽã«å€éã®æŽ»æ§æåãå«ãä»ã«ãã»ã«åŠæ¹ç©
ã¯æ¬¡ã®éãã§ããã
ãè¡šã
ããŠ
ãè¡šã
ããããã®å Žåã掻æ§æåãä¹³ç³ã殿ç²ãã
ã³ã¹ãã¢ãªã³é žãã°ãã·ãŠã ãšæ··åããåŸãæ··
åç©ãã«ãã»ã«å å¡«ããã (2) é å€ ïŒé åœãã0.5mgã®æŽ»æ§æåãå«ãé å€ã«å¯Ÿ
ãã代衚çåŠæ¹ã¯æ¬¡ã®éãã§ããããã®åŠæ¹ã¯
ãªã³é žäºã«ã«ã·ãŠã éã調æŽããããšã«ãã€ãŠ
掻æ§æå匷床ãå€ããããšãã§ããã æ å mgïŒé (1) 掻æ§æåãå¡©ãšã㊠0.5 (2) ã³ãŒã³ã¹ã¿ãŒã 13.6 (3) ã³ãŒã³ã¹ã¿ãŒãïŒããŒã¹ãïŒ 3.4 (4) ä¹³ ç³ 79.2 (5) ãªã³é žäºã«ã«ã·ãŠã 68.0 (6) ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 1.0 åèš165.7 (1)ã(2)ã(4)ããã³(5)ãåäžã«æ··åããã(3)ã
æ°Žäž10ïŒ ããŒã¹ããšããŠèª¿è£œãããåèšæ··åç©
ãã¹ã¿ãŒãããŒã¹ããšå ±ã«é¡ç²ã«ããåŸã湿ã€
ãå¡ãïŒã¡ãã·ãŠã¹ã¯ãªãŒã³ãééããããåŸ
ã湿ã€ãé¡ç²ã也ç¥ãã12ã¡ãã·ãŠã¹ã¯ãªãŒã³
ã§ãµã€ãºãæãããåŸã也ç¥é¡ç²ãã¹ãã¢ãªã³
é žã«ã«ã·ãŠã ãšæ··åããå§çž®ããã 1.0mgã2.0mgãããã³5.0mgã®æŽ»æ§æåãå«ã
ä»ã®é å€åŠæ¹ç©ã次ã®éãã«ããŠè£œé ããã (3) 泚 çš 0.05ïŒ æ» è溶液 æ å mg/c.c. 掻æ§æåãå¡©ãšã㊠0.5 é²è å€ïŒäŸãã°ã¯ãããã¿ããŒã«ïŒ
0.0125w/ml% 泚çšæ°Ž é© é 溶液ã調補ããéã«ããæŸæã«ãããã€ã¢
ã«ã«ã€ããã·ãŒã«ããå å§ããã (4) å è¬ æ å 掻æ§æå 0.10 ã«ã«ãã¯ãã¯ã¹ããªãšãã¬ã³ã°ãªã³ãŒã«1000
75.00 ã«ã«ãã¯ãã¯ã¹ããªãšãã¬ã³ã°ãªã³ãŒã«4000
25.00 ïŒã€ã®ã«ã«ãã¯ãã¯ã¹ç©è³ªãã溶èç©ãäœ
ããããã«æŽ»æ§æåãå ããŠå®å šã«æ··åããã
ããã1.0ïœå®¹éã®åã«æ³šãå ¥ããŠæŸå·ããã
åã ã®åè¬ã¯1.0mgã®æŽ»æ§æåãå«ãã§ããã ãã®çºæã®æ§ã ãªä¿®æ£ããã³åçæ¹æ³ãåçç©
ã¯åœæ¥è ã«æããã§ããããã®ç²Ÿç¥ãŸãã¯ç¯å²ã
ãé¢ããããšãªããã®çºæã®æ¹æ³ããã³çµæç©ã«
ãããŠãªãããã
ã³ã¹ãã¢ãªã³é žãã°ãã·ãŠã ãšæ··åããåŸãæ··
åç©ãã«ãã»ã«å å¡«ããã (2) é å€ ïŒé åœãã0.5mgã®æŽ»æ§æåãå«ãé å€ã«å¯Ÿ
ãã代衚çåŠæ¹ã¯æ¬¡ã®éãã§ããããã®åŠæ¹ã¯
ãªã³é žäºã«ã«ã·ãŠã éã調æŽããããšã«ãã€ãŠ
掻æ§æå匷床ãå€ããããšãã§ããã æ å mgïŒé (1) 掻æ§æåãå¡©ãšã㊠0.5 (2) ã³ãŒã³ã¹ã¿ãŒã 13.6 (3) ã³ãŒã³ã¹ã¿ãŒãïŒããŒã¹ãïŒ 3.4 (4) ä¹³ ç³ 79.2 (5) ãªã³é žäºã«ã«ã·ãŠã 68.0 (6) ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 1.0 åèš165.7 (1)ã(2)ã(4)ããã³(5)ãåäžã«æ··åããã(3)ã
æ°Žäž10ïŒ ããŒã¹ããšããŠèª¿è£œãããåèšæ··åç©
ãã¹ã¿ãŒãããŒã¹ããšå ±ã«é¡ç²ã«ããåŸã湿ã€
ãå¡ãïŒã¡ãã·ãŠã¹ã¯ãªãŒã³ãééããããåŸ
ã湿ã€ãé¡ç²ã也ç¥ãã12ã¡ãã·ãŠã¹ã¯ãªãŒã³
ã§ãµã€ãºãæãããåŸã也ç¥é¡ç²ãã¹ãã¢ãªã³
é žã«ã«ã·ãŠã ãšæ··åããå§çž®ããã 1.0mgã2.0mgãããã³5.0mgã®æŽ»æ§æåãå«ã
ä»ã®é å€åŠæ¹ç©ã次ã®éãã«ããŠè£œé ããã (3) 泚 çš 0.05ïŒ æ» è溶液 æ å mg/c.c. 掻æ§æåãå¡©ãšã㊠0.5 é²è å€ïŒäŸãã°ã¯ãããã¿ããŒã«ïŒ
0.0125w/ml% 泚çšæ°Ž é© é 溶液ã調補ããéã«ããæŸæã«ãããã€ã¢
ã«ã«ã€ããã·ãŒã«ããå å§ããã (4) å è¬ æ å 掻æ§æå 0.10 ã«ã«ãã¯ãã¯ã¹ããªãšãã¬ã³ã°ãªã³ãŒã«1000
75.00 ã«ã«ãã¯ãã¯ã¹ããªãšãã¬ã³ã°ãªã³ãŒã«4000
25.00 ïŒã€ã®ã«ã«ãã¯ãã¯ã¹ç©è³ªãã溶èç©ãäœ
ããããã«æŽ»æ§æåãå ããŠå®å šã«æ··åããã
ããã1.0ïœå®¹éã®åã«æ³šãå ¥ããŠæŸå·ããã
åã ã®åè¬ã¯1.0mgã®æŽ»æ§æåãå«ãã§ããã ãã®çºæã®æ§ã ãªä¿®æ£ããã³åçæ¹æ³ãåçç©
ã¯åœæ¥è ã«æããã§ããããã®ç²Ÿç¥ãŸãã¯ç¯å²ã
ãé¢ããããšãªããã®çºæã®æ¹æ³ããã³çµæç©ã«
ãããŠãªãããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒïŒ ïŒåŒäžR1ã¯ããã²ã³ååã§ãããïœã¯æŽæ°ïŒãïŒ
ã§ãããïŒ ã®ååç©ãæ°ŽçŽ åããŠçŽ ãããªãŠã ã§éå ããã
ãšãããªãåŒïŒ ïŒåŒäžR1ãšïœã¯åèšå®çŸ©éãã§ãããïŒ ã®ïŒã»ïŒâïŒãŸãã¯ïŒâïŒâãžçœ®æãããªãžã³é¡ã®
補æ³ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/356,975 US4101662A (en) | 1973-05-03 | 1973-05-03 | Method for inhibiting emesis and compositions therefor |
| US356975 | 1989-05-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59152371A JPS59152371A (ja) | 1984-08-31 |
| JPS6131099B2 true JPS6131099B2 (ja) | 1986-07-17 |
Family
ID=23403763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP49048887A Expired JPS6156227B2 (ja) | 1973-05-03 | 1974-05-02 | |
| JP58026887A Granted JPS59152371A (ja) | 1973-05-03 | 1983-02-19 | ïŒïŒïŒâïŒãŸãã¯ïŒâïŒâãžçœ®æãããªãžã³é¡ã®è£œæ³ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP49048887A Expired JPS6156227B2 (ja) | 1973-05-03 | 1974-05-02 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4101662A (ja) |
| JP (2) | JPS6156227B2 (ja) |
| AU (1) | AU471020B2 (ja) |
| BE (1) | BE814396A (ja) |
| FR (1) | FR2227868B1 (ja) |
| GB (1) | GB1429751A (ja) |
| IL (1) | IL44721A (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4246268A (en) * | 1979-02-09 | 1981-01-20 | Richardson-Merrell Inc. | Neuroleptic-4-(naphthylmethyl)piperidine derivatives |
| US4284636A (en) * | 1979-09-04 | 1981-08-18 | Richardson-Merrell Inc. | Cinnamoylpiperidinobutyrophenone antipsychotic agents |
| US4283404A (en) * | 1979-09-04 | 1981-08-11 | Richardson-Merrell Inc. | Aroylethenylpiperidinobutyrophenone antipsychotic agents |
| ZA806501B (en) * | 1979-10-27 | 1981-10-28 | Richardson Merrell Inc | 4-(4-alkyl-aroyl-1-piperidino)butyrophenone antipsychotic agents |
| FR2581993B1 (fr) * | 1985-05-14 | 1988-03-18 | Synthelabo | Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique |
| US5021428A (en) * | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
| KR910006138B1 (ko) * | 1986-09-30 | 1991-08-16 | ìììŽ ê°ë¶ìëŒê°ìŽì€ | íìì믌 ì ë첎 |
| JP2573195B2 (ja) * | 1986-09-30 | 1997-01-22 | ãšãŒã¶ã€æ ªåŒäŒç€Ÿ | ç°ç¶ã¢ãã³èªå°äœ |
| US4870083A (en) * | 1987-11-24 | 1989-09-26 | Merrell Dow Pharmaceuticals Inc. | 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants |
| US5523307A (en) * | 1987-11-27 | 1996-06-04 | Eisai Co., Ltd. | Cyclic amine and pharmacological composition |
| DE3854991T2 (de) * | 1987-11-27 | 1996-07-18 | Eisai Co Ltd | Cyclische Amine und pharmakologische Verbindungen |
| US5196439A (en) * | 1987-11-27 | 1993-03-23 | Eisai Co., Ltd. | Piperidine compounds useful to treat cerebrovascular diseases |
| US5162342A (en) * | 1988-01-21 | 1992-11-10 | Merrell Dow Pharmaceuticals Inc. | Use of 1,4-disubstituted-piperidinyl compounds for analgesia and muscle relaxation |
| EP0661266A1 (en) * | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
| KR20050085673A (ko) * | 2002-12-18 | 2005-08-29 | ìíì ìš ìœí¬ë ìŽì | -(ì¹íë ì늎ë©íž)-4-(ìŽì¹íë ë©íž)íŒí늬ë ë°íŒíëŒì§ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3128278A (en) * | 1964-04-07 | Substituted l | ||
| US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
| US3852455A (en) * | 1970-11-27 | 1974-12-03 | Richardson Merrell Inc | 4-{8 4({60 hydroxybenzyl)piperidino{9 -4-fluorobutyrophenone derivatives as tranquilizers |
-
1973
- 1973-05-03 US US05/356,975 patent/US4101662A/en not_active Expired - Lifetime
-
1974
- 1974-04-26 IL IL44721A patent/IL44721A/en unknown
- 1974-04-30 BE BE143784A patent/BE814396A/xx not_active IP Right Cessation
- 1974-04-30 FR FR7415029A patent/FR2227868B1/fr not_active Expired
- 1974-05-01 GB GB1909874A patent/GB1429751A/en not_active Expired
- 1974-05-02 JP JP49048887A patent/JPS6156227B2/ja not_active Expired
- 1974-05-02 AU AU68516/74A patent/AU471020B2/en not_active Expired
-
1983
- 1983-02-19 JP JP58026887A patent/JPS59152371A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6156227B2 (ja) | 1986-12-01 |
| FR2227868B1 (ja) | 1977-09-09 |
| IL44721A0 (en) | 1974-06-30 |
| AU471020B2 (en) | 1976-04-08 |
| BE814396A (fr) | 1974-08-16 |
| JPS59152371A (ja) | 1984-08-31 |
| AU6851674A (en) | 1975-11-06 |
| GB1429751A (en) | 1976-03-24 |
| IL44721A (en) | 1977-06-30 |
| JPS5018477A (ja) | 1975-02-26 |
| FR2227868A1 (ja) | 1974-11-29 |
| US4101662A (en) | 1978-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6131099B2 (ja) | ||
| DE1930818B2 (de) | 1-Substituierte 3- oder 4-Aroylpiperidine, Verfahren zu deren Herstellung und ihre Verwendung | |
| JPH0132823B2 (ja) | ||
| JPH0432821B2 (ja) | ||
| JPH0729922B2 (ja) | ïŒâã¢ã«ã³ãã·âïœâïŒïŒâã¢ã¶ãã·ã¯ãïŒïŒïŒïŒïŒãªã¯ãâïŒâã€ã«ïŒãã³ãºã¢ããé¡ããã³ããªãã³ãºã¢ããé¡ | |
| JPH0710850B2 (ja) | ã¢ãªãŒã«ãããªãžã³èªå°äœ | |
| JPS6340792B2 (ja) | ||
| US4013668A (en) | 5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds | |
| US3996214A (en) | 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto | |
| IE46737B1 (en) | 2-(2,2-diarylalkyl)-1-azabicyclo (2.2.2)octane and related compounds | |
| JPS6127388B2 (ja) | ||
| JPH0681723B2 (ja) | éâçœéæçè¬ã«ããã²ãèµ·ããããååã®è»œæžçšæ²»çå€ | |
| CA1079734A (en) | 1-(3,3,3,-triarylpropyl)-4-phenyl-4-piperidinemethanols | |
| US4021552A (en) | 10-[Ï-(BENZOYLPIPERIDINYL)ALKYL]PHENOTHIAZINES | |
| JPH0267272A (ja) | è¬ç掻æ§ã®ãããã³ãŸã€ãããŸãŒã«èªå°äœ | |
| JPS6157311B2 (ja) | ||
| US3177211A (en) | 10-[(aminocarbamyl-1-piperidyl)-loweralkyl]-phenothiazines | |
| HU198454B (en) | Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds | |
| JPS6257606B2 (ja) | ||
| US3088869A (en) | Antiemetic compositions and methods of treating nausea and vomiting | |
| US4003904A (en) | Anti-diarrheal oxadiazoles | |
| US3266988A (en) | Method of producing anti-adrenal activity | |
| US3743735A (en) | Pharmaceutical compositions containing tropanol esters of alpha-phenyl-alpha-cyclopentyl-acetic acid and methods of use | |
| IE43413B1 (en) | Heterocyclic compounds | |
| DE1545961A1 (de) | Verfahren zur Herstellung von gamma-Picolylderivaten |